Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

INSILICO Aktie

 >INSILICO Aktienkurs 
4.34 EUR    -5.2%    (TradegateBSX)
Ask: 4.34 EUR / 907 Stück
Bid: 4.26 EUR / 930 Stück
Tagesumsatz: 2816 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
INSILICO Aktie über LYNX handeln
>INSILICO Performance
1 Woche: +1,4%
1 Monat: -13,2%
3 Monate: -14,1%
6 Monate: -33,2%
1 Jahr: 0%
laufendes Jahr: 0%
>INSILICO Aktie
Name:  INSILICO MEDICINE
Land:  China
Sektor:  Gesundheit
ISIN/ Wkn:  KYG4790P1037 / A41XT7
Symbol/ Ticker:  O15 (Frankfurt)
Kürzel:  FRA:O15, ETR:O15, O15:GR
Index:  -
Webseite:  https://insilico.com/
Profil:  InSilico Medicine Cayman TopCo is an artificial intelligence-based biotechnology company focused on drug discovery and development. It leverages generative AI through its Pharma.AI platform, an end-to-end software and automation solution that enhance..
>Volltext..
Marktkapitalisierung:  2570.79 Mio. EUR
Unternehmenswert:  2074.68 Mio. EUR
Umsatz:  122.15 Mio. EUR
EBITDA:  -3.8 Mio. EUR
Nettogewinn:  -268.3 Mio. EUR
Gewinn je Aktie:  -0.48 EUR
Schulden:  17.83 Mio. EUR
Liquide Mittel:  324.33 Mio. EUR
Operativer Cashflow:  42.17 Mio. EUR
Bargeldquote:  8.47
Umsatzwachstum:  161.16%
Gewinnwachstum:  -593.45%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  INSILICO
Letzte Datenerhebung:  15.11.26
>INSILICO Kennzahlen
Aktien/ Unternehmen:
Aktien: 587.95 Mio. St.
Frei handelbar: 82.73%
Leerverk. Aktien: -
Rückkaufquote: -11.12%
Mitarbeiter: 317
Umsatz/Mitarb.: 0.16 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 106.29%
Bewertung:
KGV: -
KGV lG: 105.15
KUV: 21.8
KBV: 5.27
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 87.95%
Gewinnmarge: -219.64%
Operative Marge: -6.84%
Managementeffizenz:
Gesamtkaprendite: -68.7%
Eigenkaprendite: -
>INSILICO Peer Group
Gesundheit, Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika, Autoimmunerkrankungen, Onkologie/ Krebs- Behandlung
 
16.11.26 - 02:00
INSILICO Repurchases 300,000 Shares Last Fri for Over HKD11.2 million (AAStocks)
 
INSILICO (03696.HK) announced that it repurchased 300,000 shares last Fri (13th), at prices ranging from HKD37.2 to HKD37.5 per share, involving approximately HKD11.2033 million.AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by AI, the Chinese version should be considered the authoritat......
13.11.26 - 10:00
INSILICO Enters Strategic AI Drug Development Partnership With Luoxin Pharmaceutical (AAStocks)
 
INSILICO (03696.HK) announced that its wholly owned subsidiary Insilico Technology (Shanghai) recently signed a strategic cooperation agreement with Luoxin Pharmaceutical.The two parties plan to establish a long-term strategic partnership focused on innovative drug research and development, promoting the deep integration of arti......
10.11.26 - 02:15
INSILICO Spends HKD7.562 Million to Buy Back 199,000 Shares on Mon (AAStocks)
 
INSILICO (03696.HK) announced that it repurchased 199,000 shares on Nov 9 at HKD38 per share, involving approximately HKD7.562 million. Since the repurchase mandate resolution was approved on Jun 2, 2026, the group has cumulatively repurchased 599,000 shares, accounting for 0.1046% of issued shares. (da)~AASTOCKS Financial NewsW......
09.11.26 - 01:45
INSILICO Repurchased 400,000 Shares Last Fri for HKD15.0059 million (AAStocks)
 
INSILICO (03696.HK) announced that it repurchased 400,000 shares on November 6 at prices ranging from HKD36.921 to HKD38.3 per share, involving approximately HKD15.0059 million.Since the ordinary resolution was passed on June 2, 2026, the group has cumulatively repurchased 400,000 shares, representing 0.0699% of its issued share......
06.11.26 - 15:01
Insilico Open-Sources 24/7 Personal Longevity Superintelligence to Turn Quantified-Self Data into Predictive Health States and Aging Research (PR Newswire)
 
CAMBRIDGE, Mass., Nov. 6, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage generative AI drug discovery company, today announced the open-source release of Longevity Grok, the Personal Longevity Superintelligence (PLSI) and launched the website longevitygrok.si, in collaboration......
27.10.26 - 03:00
INSILICO Releases Preliminary Data From Phase I Human Clinical Trial of ISM6331 (AAStocks)
 
INSILICO (03696.HK) announced that preliminary positive data from the first-in-human Phase I clinical trial of ISM6331, an orally administered pan-TEAD inhibitor designed using generative AI, was presented at the European Society for Medical Oncology (ESMO) Congress 2026. As of the data cutoff date (Aug 14, 2026), the objective ......
13.10.26 - 03:30
INSILICO Nominates VAV1 Molecular Glue Degrader ISM9546 as Preclinical Candidate (AAStocks)
 
INSILICO (03696.HK) announced the nomination of ISM9546 as a preclinical candidate (PCC). The product is an innovative, oral, peripheral-restricted VAV1 molecular glue degrader with potential applications in the treatment of multiple autoimmune diseases, including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA).IN......
30.09.26 - 08:00
Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist (PR Newswire)
 
CAMBRIDGE, Mass., Sept. 30, 2026 /PRNewswire/ -- As population aging accelerates with demand for weight management continuing to expand, the market for GLP-1 receptor agonist (GLP-1RA) drugs is experiencing explosive growth. Tirzepatide, with annual sales of $36.507 billion in 2025, has......
30.09.26 - 06:30
INSILICO Nominates Next-Generation Small Molecule GIPR Antagonist (AAStocks)
 
INSILICO (03696.HK) announced the nomination of ISM1354 as a preclinical candidate compound (PCC), with potential applications in interventions for obesity, type 2 diabetes and related diseases, and possible expansion into the cardiovascular disease field. The company has announced the nomination of 10 PCCs in the first nine mon......
24.09.26 - 07:15
Research: Jefferies: INSILICO Has Strong Business Development Momentum, Drug Assets More Important Than Proprietary Models (AAStocks)
 
Jefferies said in a research report that INSILICO (03696.HK) management reiterated at the broker's Asia Pacific healthcare conference that the company is shifting from platform validation toward asset and recurring milestone monetization. Business development momentum remains strong, with the China Phase III clinical trial of AI......
21.09.26 - 07:45
Research: JPM: INSILICO Longevity Research Broadens AIDD Platform Applications; Maintains Overweight Rating (AAStocks)
 
JPMorgan published a report stating that INSILICO (03696.HK)'s recent progress in longevity research has reinforced its differentiated advantages in the AI-driven drug discovery (AIDD) industry. JPM noted that a cover study published in Cell last Thursday (17th) introduced the aging-related benchmark dataset LongevityBench, dedi......
21.09.26 - 06:45
INSILICO Reaches AI Joint Development Partnership With Contract Value Up to Tens of Millions of USD (AAStocks)
 
INSILICO (03696.HK) announced that it has reached an AI joint development partnership with a frontier foundation model laboratory, with the contract value reaching up to tens of millions of USD.Under the agreement, the two parties will jointly develop, validate and commercialize a series of frontier foundation models tailored fo......
18.09.26 - 06:30
Research: Daiwa: INSILICO BD and PCC Output Hit Record High (AAStocks)
 
Daiwa released a report saying that INSILICO (03696.HK) achieved record-high BD and PCC output, while its revenue surge in 1H26 was mainly driven by accelerated out-licensing activities. Revenue in the first half of the year jumped 287.2% YoY to USD106 million, supported by strong growth in its core drug discovery and pipeline d......
17.09.26 - 17:27
Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study (PR Newswire)
 
The paper introduces three interconnected resources for the global scientific community: LongevityBench, the first open benchmark designed to rigorously evaluate AI reasoning across multiple domains of aging biology; Longevity-LLMs, a family of compact, open-source language models......
10.09.26 - 05:30
An AI-Designed Drug Just Moved Six Different Aging Clocks At Once (ZeroHedge)
 
An AI-Designed Drug Just Moved Six Different Aging Clocks At Once An experimental drug designed using AI has produced measurable shifts toward a younger biological-age profile in patients. Developed by Insilico Medicine, the drug - rentosertib - was initially engineered to treat idiopathic pulmonary fibrosis (IPF), a progressive, age-associated lung-scarring disease. When researchers analyzed blood samples from a Phase IIa clinical trial, they applied six proteomic profiling "aging clocks" among 42 participants. All six detected reductions in predicted biological age, whereas the placebo group showed little change or slight increases. The most pronounced and consistent effects emerged around week four of treatment. The study was authored by Insilico with academic collaborators from Harvard, Stanford, the Broad Institute, RWTH Aachen, Peking University and Westlake University. Insilico used AI not only to identify a specific enzyme (TNIK) linked to both fibrosis and aging pathways, ...
10.09.26 - 03:45
INSILICO Completes First Patient Enrollment and Dosing in Phase III Clinical Trial of Rentosertib for Idiopathic Pulmonary Fibrosis (AAStocks)
 
INSILICO (03696.HK) announced that AI-driven investigational drug candidate Rentosertib (also known as ISM001-055/INS018_055) has completed the enrollment and dosing of the first patient in its Phase III clinical trial (GENESIS-IPF-3) at Peking Union Medical College Hospital. On the same day, Shanghai Pulmonary Hospital also com......
10.09.26 - 02:36
Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World′s First Phase III Trial of a Generative AI-Driven Innovative Drug (PR Newswire)
 
CAMBRIDGE, Mass., Sept. 9, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase......
09.09.26 - 09:45
Research: Citi: New Biomarker Evidence for INSILICO 's Rentosertib Supports Potential Anti-aging Effects (AAStocks)
 
Citi published a report on research related to INSILICO (03696.HK)'s Rentosertib, stating that the findings positively validate the company's senescence biology-led discovery approach and further highlight the differentiated advantages of its lead asset. Consistent signals were observed across six independently developed aging c......
08.09.26 - 08:54
KI-Pharmasparte: Citi kürt Insilico zum Top-Pick in China (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
08.09.26 - 07:01
Can Insilico′s Drug Help Turn Back the Biological Clock? | The China Show | 9/8/2026 (Bloomberg)
 
“Bloomberg: The China Show” is your definitive source for news and analysis on the world's second-biggest economy. From politics and policy to tech and trends, Yvonne Man and David Ingles give global investors unique insight, delivering in-depth discussions with the newsmakers who matter. (Source: Bloomberg)...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Geschmack hängt nicht an unseren Bedürfnissen. Der Mann muß schon sehr gesittet sein, wenn er eine Frau nach Geschmack wählen soll. - Immanuel Kant
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!